VJHemOnc is committed to improving our service to you

ASH 2019 | Nivo and dara +/- cyclophosphamide in R/R MM

VJHemOnc is committed to improving our service to you

Niels van de Donk

Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses a prospective, multicenter, phase II trial (NCT03184194). This study investigated the efficacy and safety of daratumumab combined with nivolumab, with or without low-dose cyclophosphamide, in patients with relapsed/refractory multiple myeloma (MM). Results indicate that the combination of daratumumab and nivolumab may be a new therapeutic regimen with an acceptable safety profile. However, the addition of low-dose cyclophosphamide did not improve efficacy, and increased the frequency of infections and hematologic toxicity. Therefore, the nivolumab-daratumumab regimen was selected for further evaluation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter